For the First Time, AI Analyzes Language as Well as a Human Expert

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...
American Association of Individual Investors

Which Is a Better Investment, Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. Stock?

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Momus

Go on Without Me: Summer Kim Lee and TJ Shin on Absenteeism, Endlessness, and Recursion

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that ...
GEN - Genetic Engineering and Biotechnology News

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...